

Incyte Biosciences Denmark ApS

Suomisvej 4, 1927 Frederiksberg C


Company reg. no. 35 81 87 90

Annual report

1 January - 31 December 2022

The annual report was submitted and approved by the general meeting on the 16/05/2023

DocuSigned by:



Jonathan Dickinson

Chairman of the meeting

Contents

| | <u>Page</u> |
|---|--------------------|
| <i>Reports</i> | |
| <i>Management's statement</i> | 1 |
| <i>Practitioner's compilation report</i> | 2 |
| <i>Management's review</i> | |
| <i>Company information</i> | 3 |
| <i>Management's review</i> | 4 |
| <i>Financial statements 1 January - 31 December 2022</i> | |
| <i>Income statement</i> | 5 |
| <i>Balance sheet</i> | 6 |
| <i>Statement of changes in equity</i> | 8 |
| <i>Notes</i> | 9 |
| <i>Accounting policies</i> | 10 |

Notes:

- To ensure the greatest possible applicability of this document, IAS/IFRS English terminology has been used.
- Please note that decimal points have not been used in the usual English way. This means that for instance DKK 146.940 means the amount of DKK 146,940, and that 23,5 % means 23.5 %.

Management's statement

Today, the Board of Directors and the Managing Director have approved the annual report of Incyte Biosciences Denmark ApS for the financial year 1 January - 31 December 2022.

The annual report has been prepared in accordance with the Danish Financial Statements Act.

We consider the chosen accounting policy to be appropriate, and in our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2022 and of the results of the Company's operations for the financial year 1 January – 31 December 2022.


The Board of Directors and the Managing Director consider the conditions for audit exemption of the 2022 financial statements to be met.

Further, in our opinion, the Management's review gives a true and fair review of the matters discussed in the Management's review.

We recommend that the annual report be approved at the Annual General Meeting.

Frederiksberg C, May 15, 2023


Managing Director

DocuSigned by:

Erik Thomas Frømm

Board of directors

DocuSigned by:

Jonathan Elliot Dickinson

DocuSigned by:

Erik Thomas Frømm

Practitioner's compilation report

To the Shareholders of Incyte Biosciences Denmark ApS

We have compiled the financial statements of Incyte Biosciences Denmark ApS for the financial year 1 January - 31 December 2022 based on the company's bookkeeping and on information you have provided.

These financial statements comprise income statement, balance sheet, statement of changes in equity, notes and a summary of significant accounting policies.

We performed this compilation engagement in accordance with International Standard on Related Services 4410 (Revised), Compilation Engagements.

We have applied our expertise in accounting and financial reporting to assist Management in the preparation and presentation of these financial statements in accordance with the Danish Financial Statements Act. We have complied with relevant requirements under the Danish Act on Approved Auditors and Audit Firms and International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) including principles of integrity, objectivity, professional competence and due care.

These financial statements and the accuracy and completeness of the information used to compile them are your responsibility.

Since a compilation engagement is not an assurance engagement, we are not required to verify the accuracy or completeness of the information you provided to us to compile these financial statements. Accordingly, we do not express an audit opinion or a review conclusion on whether these financial statements are prepared in accordance with the Danish Financial Statements Act.

Copenhagen,

Grant Thornton

*State Authorised Public Accountants
Company reg. no. 34 20 99 36*

Steen K. Bager

*State Authorised Public Accountant
mne28679*

Company information

The company

Incyte Biosciences Denmark ApS
Suomisvej 4
1927 Frederiksberg C

Company reg. no. 35 81 87 90

Established: 1 April 2014

Financial year: 1 January - 31 December

Board of directors

Jonathan Elliot Dickinson
Erik Thomas Fromm

Managing Director

Erik Thomas Fromm

Auditors

Grant Thornton, Statsautoriseret Revisionspartnerselskab
Stockholmsgade 45
2100 København Ø

Management's review

The principal activities of the company

Like previous years, the activities are to promote medical and pharmaceutical knowledge and activities along with trade of pharmaceuticals as well as any business associated herewith.

Development in activities and financial matters

The gross profit for the year totals DKK 5.556.640 against DKK 5.287.823 last year. Income or loss from ordinary activities after tax totals DKK 277.949 against DKK 268.531 last year. Management considers the net profit or loss for the year satisfactory.

Income statement 1 January - 31 December*All amounts in DKK.*

| <u>Note</u> | <u>2022</u> | <u>2021</u> |
|--|------------------|------------------|
| <i>Gross profit</i> | 5.556.640 | 5.287.823 |
| 1 <i>Staff costs</i> | -5.185.159 | -4.924.198 |
| <i>Operating profit</i> | 371.481 | 363.625 |
| <i>Other financial expenses</i> | -16.856 | -18.050 |
| <i>Pre-tax net profit or loss</i> | 354.625 | 345.575 |
| 2 <i>Tax on net profit for the year</i> | -76.676 | -77.044 |
| <i>Net profit or loss for the year</i> | 277.949 | 268.531 |
| <i>Proposed distribution of net profit:</i> | | |
| <i>Transferred to retained earnings</i> | 277.949 | 268.531 |
| <i>Total allocations and transfers</i> | 277.949 | 268.531 |

Balance sheet at 31 December

All amounts in DKK.

| <u>Note</u> | <u>2022</u> | <u>2021</u> |
|---------------------------------|------------------|------------------|
| Assets | | |
| Non-current assets | | |
| Deposits | 37.247 | 23.175 |
| Total investments | 37.247 | 23.175 |
| Total non-current assets | 37.247 | 23.175 |
| Current assets | | |
| Receivables from subsidiaries | 5.462.062 | 2.046.450 |
| Income tax receivables | 12.000 | 0 |
| Other receivables | 826.421 | 306.921 |
| Prepayments | 0 | 128.824 |
| Total receivables | 6.300.483 | 2.482.195 |
| Cash and cash equivalents | 653.424 | 936.823 |
| Total current assets | 6.953.907 | 3.419.018 |
| Total assets | 6.991.154 | 3.442.193 |

Balance sheet at 31 December

All amounts in DKK.

| <u>Note</u> | <u>2022</u> | <u>2021</u> |
|---|------------------|------------------|
| Equity and liabilities | | |
| Equity | | |
| Contributed capital | 50.000 | 50.000 |
| Retained earnings | 1.173.888 | 895.939 |
| Total equity | 1.223.888 | 945.939 |
| Liabilities other than provisions | | |
| Trade payables | 170.883 | 352.779 |
| Payables to subsidiaries | 4.436.293 | 500.000 |
| Income tax payable | 0 | 59.044 |
| Other payables | 1.160.090 | 1.584.431 |
| Total short term liabilities other than provisions | 5.767.266 | 2.496.254 |
| Total liabilities other than provisions | 5.767.266 | 2.496.254 |
| Total equity and liabilities | 6.991.154 | 3.442.193 |

3 Contingencies

Statement of changes in equity*All amounts in DKK.*

| | <u>Contributed capital</u> | <u>Retained earnings</u> | <u>Total</u> |
|---------------------------------------|----------------------------|--------------------------|-------------------------|
| <i>Equity 1 January 2022</i> | 50.000 | 895.939 | 945.939 |
| <i>Retained earnings for the year</i> | <u>0</u> | <u>277.949</u> | <u>277.949</u> |
| | <u>50.000</u> | <u>1.173.888</u> | <u>1.223.888</u> |

Notes*All amounts in DKK.*

| | <u>2022</u> | <u>2021</u> |
|--|-------------------------|-------------------------|
| 1. Staff costs | | |
| Salaries and wages | 4.680.327 | 4.455.161 |
| Pension costs | 505.465 | 477.412 |
| Other costs for social security | <u>-633</u> | <u>-8.375</u> |
| | <u>5.185.159</u> | <u>4.924.198</u> |
| Average number of employees | <u>4</u> | <u>4</u> |
| 2. Tax on net profit for the year | | |
| Tax on net profit or loss for the year | <u>76.676</u> | <u>77.044</u> |
| | <u>76.676</u> | <u>77.044</u> |

3. Contingencies**Contingent liabilities***Lease liabilities:*

The company has entered into operational leases with an average annual lease payment of k.DKK 144. The leases have 10 months to maturity and total outstanding lease payments total k.DKK 120.

Other contingent liabilities:

The company has entered into a contract regarding houserent. There is a minimum payment of k.DKK 36 and a minimum of three months left of the contract.

Accounting policies

The annual report for Incyte Biosciences Denmark ApS has been presented in accordance with the Danish Financial Statements Act regulations concerning reporting class B enterprises.

The accounting policies are unchanged from last year, and the annual report is presented in DKK.

Recognition and measurement in general

Income is recognised in the income statement concurrently with its realisation, including the recognition of value adjustments of financial assets and liabilities. Likewise, all costs are recognised in the income statement, including depreciations amortisations, writedowns for impairment, provisions, and reversals due to changes in estimated amounts previously recognised in the income statement.

Assets are recognised in the statement of financial position when it seems probable that future economic benefits will flow to the company and the value of the asset can be reliably measured.

Liabilities are recognised in the statement of financial position when it is seems probable that future economic benefits will flow out of the company and the value of the liability can be reliably measured.

Assets and liabilities are measured at cost at the initial recognition. Hereafter, assets and liabilities are measured as described below for each individual accounting item.

Upon recognition and measurement, allowances are made for such predictable losses and risks which may arise prior to the presentation of the annual report and concern matters that exist on the reporting date.

Foreign currency translation

Transactions in foreign currency are translated by using the exchange rate prevailing at the date of the transaction. Differences in the rate of exchange arising between the rate at the date of transaction and the rate at the date of payment are recognised in the profit and loss account as an item under net financials. If currency positions are considered to hedge future cash flows, the value adjustments are recognised directly in equity in a fair value reserve.

Receivables, payables, and other foreign currency monetary items are translated using the closing rate. The difference between the closing rate and the rate at the time of the occurrence or initial recognition in the latest financial statements of the receivable or payable is recognised in the income statement under financial income and expenses.

Income statement

Gross profit

Gross profit comprises the revenue, other operating income, and external costs.

Accounting policies

Revenue is recognised in the income statement if delivery and passing of risk to the buyer have taken place before the end of the year and if the income can be determined reliably and inflow is anticipated. Revenue is measured at the fair value of the consideration promised exclusive of VAT and taxes and less any discounts relating directly to sales.

Other external expenses comprise expenses incurred for distribution, sales, advertising, administration, premises, loss on receivables, and operational leasing costs.

Staff costs

Staff costs include salaries and wages, including holiday allowances, pensions, and other social security costs, etc., for staff members.

Financial income and expenses

Financial income and expenses are recognised in the income statement with the amounts concerning the financial year.

Tax on net profit or loss for the year

Tax for the year comprises the current income tax for the year and changes in deferred tax and is recognised in the income statement with the share attributable to the net profit or loss for the year and directly in equity with the share attributable to entries directly in equity.

Statement of financial position

Leases

Leases are regarded as operating leases. Payments in connection with operating leases and other lease agreements are recognised in the income statement for the term of the contract. The company's total liabilities concerning operating leases and lease agreements are recognised under contingencies, etc.

Investments

Deposits

Deposits are measured at amortised cost and represent lease deposits, etc.

Receivables

Receivables are measured at amortised cost, which usually corresponds to nominal value.

Prepayments

Prepayments recognised under assets comprise incurred costs concerning the following financial year.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and on hand.

Accounting policies

Income tax and deferred tax

Current tax liabilities and current tax receivable are recognised in the statement of financial position as calculated tax on the taxable income for the year, adjusted for tax of previous years' taxable income and for tax paid on account.

Liabilities other than provisions

Other liabilities are measured at amortised cost which usually corresponds to the nominal value.

Penneo

Underskrifterne i dette dokument er juridisk bindende. Dokumentet er underskrevet via Penneo™ sikker digital underskrift. Underskrivernes identiteter er blevet registereret, og informationerne er listet herunder.

"Med min underskrift bekræfter jeg indholdet og alle datoer i dette dokument."

Steen K. Bager

Statsautoriseret revisor

Serienummer: CVR:34209936-RID:81358030

IP: 62.243.xxx.xxx

2023-05-17 06:31:19 UTC

NEM ID 

Dette dokument er underskrevet digitalt via **Penneo.com**. Signeringsbeviserne i dokumentet er sikret og valideret ved anvendelse af den matematiske hashværdi af det originale dokument. Dokumentet er låst for ændringer og tidsstemplet med et certifikat fra en betroet tredjepart. Alle kryptografiske signeringsbeviser er indlejret i denne PDF, i tilfælde af de skal anvendes til validering i fremtiden.

Sådan kan du sikre, at dokumentet er originalt

Dette dokument er beskyttet med et Adobe CDS certifikat. Når du åbner dokumentet

i Adobe Reader, kan du se, at dokumentet er certificeret af **Penneo e-signature service** <penneo@penneo.com>. Dette er din garanti for, at indholdet af dokumentet er uændret.

Du har mulighed for at efterprøve de kryptografiske signeringsbeviser i indlejret i dokumentet ved at anvende Penneos validator på følgende websted: <https://penneo.com/validator>